Randomized Controlled Double Blind Study of Bee Venom Therapy on Adhesive Capsulitis of the Shoulder
The purpose of this study is to evaluate the effectiveness of combined bee venom acupuncture (BVA) and physiotherapy (PT) on frozen shoulder, and whether if the effect of BVA is dose effective.
NCT01526031 — Frozen Shoulder
Status: Completed
http://inclinicaltrials.com/frozen-shoulder/NCT01526031/
Clinical Research on the Efficacy of East-West Collaborative Medicine Using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders After Traffic Collisions; A Randomized, Controlled, Parallel Trial
1. Purpose of study 1. To evaluate the efficacy of East-West collaborative medicine using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders using VAS scale 2. To evaluate the efficacy of East-West collaborative medicine using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders using NDI, BDI, SF-36, and EQ-5D. 2. Interventions & Groups 1. group 1: Bee-Venom Acupuncture Therapy 2. group 2: zaltoprofen 3. group 3: Bee-Venom Acupuncture Therapy & zaltoprofen
NCT01369238 — Whiplash Injuries
Status: Not yet recruiting
http://inclinicaltrials.com/whiplash-injuries/NCT01369238/
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Venom immunotherapy (VIT) is an established treatment for Hymenoptera venom allergy and provides long-term protection from further generalized reactions in almost all patients. However, it is still unclear why bee VIT is less effective than vespid VIT. The preliminary data show that not only predominant Api m 10 sensitization but also other predominant sensitizations may be relevant as risk factors for treatment failure. Interestingly, all patients with a predominant Api m 10 sensitization who received bee VIT with a venom preparation with a supposed lack of Api m 10 tolerated sting challenges. Therefore, a multicenter study with a sufficient number of patients with treatment failure is urgently required, to clarify if predominant sensitization to a bee venom allergen is a risk factor for treatment failure. If predominant sensitization is a risk factor and caused by underrepresented components in bee venom preparations used for VIT, bee venom preparations may be optimized in the future and patients would benefit from a more effective VIT.
NCT04259359 — Bee Venom Allergy
Status: Recruiting
http://inclinicaltrials.com/bee-venom-allergy/NCT04259359/